|

Recombinant oncolytic herpes simplex virus type Ⅰ (R130) Clinical Trials

2 actively recruiting trials

Also known as: Oncolytic virus Injection

Pipeline

Early 1: 2

Top Sponsors

  • Shanghai Yunying Medical Technology2

Indications

  • Bone Tumor2
  • Sarcoma2
  • Osteosarcoma2
  • Cancer2
  • Sarcoma,Soft Tissue1

Other2 trials

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
Early 1
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.